Island Forest Enterprises

Island Forest Enterprises was a biotechnology company and a subsidiary of Life Biosciences, focused on the development of rejuvenation therapeutics to combat aging. The company's research centered on epigenetic reprogramming and the use of small molecules to influence the biological pathways that regulate the aging process. Operating within the Life Biosciences 'hub-and-spoke' model, Island Forest aimed to translate cutting-edge longevity science into clinical applications for age-related diseases. In 2021, Life Biosciences consolidated its various daughter companies, including Island Forest, into a single entity to streamline its research and development pipeline. Consequently, Island Forest's technologies and programs are now integrated into the core operations of Life Biosciences.